Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CSPC Pharmaceutical Group Limited (CHJTF)
Shijiazhuang, CN
CSPC Pharmaceutical Group Limited operates as an investment holding company with a core focus on the research, development, manufacturing, and global commercialization of pharmaceutical products. Its extensive operations span the People's Republic of China, other Asian markets, the Americas, Europe, and various international territories. The company segments its business into Finished Drugs, Bulk Products, and Functional Food and Others. Within its diverse portfolio of finished drug products, CSPC addresses a wide array of medical conditions. Notable offerings include NBP soft capsules and injections for acute ischemic stroke, Oulaining capsules and injections designed for mild to moderate memory and mental impairment, and Enxi to manage adult idiopathic Parkinson's disease. In the oncology sector, the company provides treatments like Duomeisu for lymphomas, multiple myeloma, ovarian, and breast cancers, alongside other malignant tumors, as well as Keaili specifically for breast cancer. Additionally, Jinyouli helps prevent leucopenia and infection induced by chemotherapy. Furthermore, CSPC's product range extends to various anti-infectives, such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is targeted with Xuanning for hypertension and Encun, aimed at preventing atherosclerotic thrombosis events. For metabolic disorders, Linmeixin and Shuanglexin assist in diabetes management, while Gubang and Gubangjia treat osteoporosis in postmenopausal women. The company also offers solutions for pain and inflammation, including Qixiao for upper respiratory tract infections and Gaoshunsong, which provides relief for numerous musculoskeletal and inflammatory conditions such like different forms of arthritis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, low back pain, sprains, strains, and other soft tissue injuries. Beyond these, CSPC's therapeutic offerings feature Debixin for various ulcer conditions and Qimaite for both acute and chronic pain management. The company is also a producer of active pharmaceutical ingredients (APIs), including antibiotics, vitamin C, and caffeine, in addition to manufacturing functional food items and glucose products, and providing healthcare services. Initially incorporated in 1992 as China Pharmaceutical Group Limited, the company underwent a rebranding in March 2013 to become CSPC Pharmaceutical Group Limited. Its corporate headquarters are located in Shijiazhuang, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -23.91% | +10.53% | +10.53% | +29.63% | +6.06% | -26.06% | +48.24% | +1,066.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - General: +6.6%-18.0% Q4'25: +65.0% (vs Q4'23)
-
EPS growth Drug Manufacturers - General: +18.2%-15.4% Q4'25: -66.7% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+15.9% Q4'25: +15.9% (vs Q4'23)
-
EBIT margin Drug Manufacturers - General: +19.4%+15.3% Q4'25: +11.0% (vs Q4'23)
-
ROIC Drug Manufacturers - General: +10.2%+11.8% ★ Q4'25: +16.1% (vs Q4'23)
-
Share dilution Drug Manufacturers - General: +0.0%-2.7% ★ Q4'25: -2.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.12× ★ Q4'25: 0.08× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 22 Rev. Ana. 1 EPS Ana. |
Dec 2027 20 Rev. Ana. 1 EPS Ana. |
Dec 2028 10 Rev. Ana. 1 EPS Ana. |
Dec 2029 11 Rev. Ana. 1 EPS Ana. |
Dec 2030 11 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.54B
est: 11.76B (-18.9%)
|
11.08B
est: 12.44B (-10.9%)
|
12.92B
est: 14.85B (-13.0%)
|
18.47B
est: 21.00B (-12.1%)
|
25.06B
est: 25.90B (-3.2%)
|
29.62B
est: 30.84B (-4.0%)
|
34.19B
est: 34.27B (-0.2%)
|
35.01B
est: 35.35B (-0.9%)
|
34.60B
est: 35.04B (-1.2%)
|
30.87B
est: 31.37B (-1.6%)
|
25.33B
est: 30.99B (-18.3%)
|
36.74B
32.60B – 44.33B
+18.5% YoY
|
35.25B
27.40B – 46.21B
-4.1% YoY
|
37.81B
31.48B – 47.60B
+7.3% YoY
|
45.64B
37.99B – 57.45B
+20.7% YoY
|
50.76B
42.26B – 63.90B
+11.2% YoY
|
| EBITDA |
2.76B
est: 2.97B (-7.0%)
|
3.25B
est: 3.14B (+3.5%)
|
4.19B
est: 3.74B (+11.9%)
|
5.32B
est: 5.30B (+0.4%)
|
5.35B
est: 6.53B (-18.0%)
|
8.09B
est: 7.78B (+4.0%)
|
9.28B
est: 8.64B (+7.4%)
|
8.66B
est: 8.91B (-2.9%)
|
8.53B
est: 8.83B (-3.4%)
|
6.86B
est: 7.49B (-8.4%)
|
5.24B
est: 7.40B (-29.2%)
|
8.78B
7.79B – 10.59B
+18.5% YoY
|
8.42B
6.54B – 11.04B
-4.1% YoY
|
9.03B
7.52B – 11.37B
+7.3% YoY
|
10.90B
9.08B – 13.72B
+20.7% YoY
|
12.13B
10.09B – 15.26B
+11.2% YoY
|
| EBIT |
2.17B
est: 2.59B (-16.2%)
|
2.66B
est: 2.74B (-2.9%)
|
3.52B
est: 3.27B (+7.6%)
|
4.59B
est: 4.62B (-0.7%)
|
4.66B
est: 5.70B (-18.2%)
|
6.50B
est: 6.78B (-4.2%)
|
7.67B
est: 7.54B (+1.7%)
|
7.61B
est: 7.78B (-2.2%)
|
7.42B
est: 7.71B (-3.8%)
|
5.71B
est: 6.34B (-9.9%)
|
3.87B
est: 6.26B (-38.2%)
|
7.42B
6.59B – 8.96B
+18.5% YoY
|
7.12B
5.53B – 9.34B
-4.1% YoY
|
7.64B
6.36B – 9.62B
+7.3% YoY
|
9.22B
7.68B – 11.61B
+20.7% YoY
|
10.26B
8.54B – 12.91B
+11.2% YoY
|
| Net Income |
1.39B
est: 1.74B (-19.8%)
|
1.88B
est: 2.12B (-11.4%)
|
2.32B
est: 2.74B (-15.5%)
|
3.08B
est: 3.52B (-12.5%)
|
4.63B
est: 4.34B (+6.7%)
|
5.16B
est: 5.38B (-4.1%)
|
6.88B
est: 6.74B (+2.1%)
|
6.89B
est: 6.69B (+3.0%)
|
5.87B
est: 6.68B (-12.1%)
|
4.61B
est: 4.89B (-5.8%)
|
3.78B
est: 5.56B (-32.0%)
|
8.84B
6.92B – 11.82B
+59.0% YoY
|
6.66B
5.21B – 8.90B
-24.7% YoY
|
7.46B
5.83B – 9.97B
+12.0% YoY
|
10.86B
8.50B – 14.51B
+45.6% YoY
|
12.67B
9.91B – 16.93B
+16.6% YoY
|
| SGA |
2.80B
est: 4.23B (-33.7%)
|
3.34B
est: 4.47B (-25.2%)
|
5.02B
est: 5.34B (-6.0%)
|
7.79B
est: 7.54B (+3.2%)
|
10.59B
est: 9.30B (+13.8%)
|
10.32B
est: 11.08B (-6.8%)
|
14.05B
est: 12.31B (+14.2%)
|
13.03B
est: 12.70B (+2.6%)
|
11.36B
est: 12.58B (-9.7%)
|
10.37B
est: 10.84B (-4.3%)
|
7.09B
est: 10.71B (-33.8%)
|
12.69B
11.26B – 15.31B
+18.5% YoY
|
12.18B
9.46B – 15.96B
-4.1% YoY
|
13.06B
10.87B – 16.44B
+7.3% YoY
|
15.77B
13.13B – 19.85B
+20.7% YoY
|
17.54B
14.60B – 22.07B
+11.2% YoY
|
| EPS |
0.12
est: 0.15 (-19.0%)
|
0.16
est: 0.18 (-11.5%)
|
0.20
est: 0.23 (-14.3%)
|
0.27
est: 0.30 (-10.0%)
|
0.35
est: 0.37 (-5.3%)
|
0.43
est: 0.46 (-6.2%)
|
0.47
est: 0.57 (-18.1%)
|
0.51
est: 0.57 (-10.6%)
|
0.49
est: 0.57 (-13.9%)
|
0.39
est: 0.43 (-8.9%)
|
0.33
est: 0.49 (-32.2%)
|
0.77
0.61 – 1.03
+59.0% YoY
|
0.58
0.46 – 0.78
-24.7% YoY
|
0.65
0.51 – 0.87
+12.0% YoY
|
0.95
0.74 – 1.27
+45.6% YoY
|
1.11
0.87 – 1.48
+16.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dongchen Cai | Executive Chairman | 2M | male |
| Chunlei Li | Executive Director & Chief Scientist | 940.8K | male |
| Huaiyu Wang | Executive Director | 803.0K | male |
| Bing Yao | Executive Director | 803.0K | male |
| Cuilong Zhang | Executive Director | 803.0K | male |
| Weiping Chen | Executive Director | 803.0K | male |
| Xin Cai | Executive Director | 803.0K | male |
| Yiwei Zhang | Executive Director | 803.0K | male |
| Zhenguo Wang | Executive Director | 803.0K | male |
| Lei Cai | CEO & Vice Chairman of the Board | 75.6K | — |
| Qingjie Wei | COO & Vice-Chairman of the Board | 71.2K | male |
| Qingjei Wei | COO, Executive Director & Vice-Chairman of the Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CHJTF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
